CRP and diabetes mellitus: In the STEP HFpEF and STEP HFpEF DM trials, semaglutide produced clinically meaningful increases in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), reduced C-reactive protein (CRP) by over 40%, and improved 6-minute walk distance.